Kairos Pharma reported strong safety results from a Phase 2 trial of ENV-105 in mCRPC, with no serious toxicities seen in the first 10 patients.
Why Is Kairos Pharma Stock Surging On Tuesday?
Where Today's News Shapes Tomorrow
March 4, 2026
Headlines
